Evaluting safety of Radium-223 in Patients with Prostate Cancer and Bone Metastases

What we are studying

The purpose of the study is to evaluate the short and long term safety profile of Radium-223 under routine practice conditions.

Who we are studying

  • Men
  • Races:
    • White
    • African American
    • Asian
    • American Indian or Alaska Native
    • Native Hawaiian or Pacific Islander
    • Other
  • All Ethnicities
  • Ages 18+

Eligibility Criteria

  • Prior decision to recieve Radium-223 treatment
  • Castration resistant adenocarcinoma of the prostate
  • Bone metastases

What is involved

  • Questionnaires



Contact Information

Study Coordinator
Patricia Smith, RN

Disclaimer: The information on this website is for general informational purposes only and SHOULD NOT be relied upon as a substitute for sound professional medical advice, evaluation or care from your physician or other qualified health care provider.